Louisiana Healthcare Connections Policies and Procedures Updates
Date: 05/20/25
Louisiana Healthcare Connections is sharing with providers the below policies and procedures that were developed and/or revised; posted for public comment and approved by LDH in accordance with La. R.S. 46:460.54. Non-material revisions do not require LDH approvals.
Please share this notice with other members of your practice and office staff as necessary.
These guidelines will be implemented 30 days from the date of this notice and will be posted on our Clinical & Payment Policies page.
| Policy & Procedure # | Policy & Procedure Title | New, material revisions, non-manterial revisions |
|---|---|---|
| LA.PHAR.119 | Ramucirumab (Cyramza) | Material |
| LA.PHAR.160 | Alglucosidase Alfa (Lumizyme) | Material |
| LA.PHAR.187 | Verteporfin (Visudyne) | Material |
| LA.PHAR.192 | Epoprostenol (Flolan, Veletri) | Material |
| LA.PHAR.203 | Cosyntropin (Cortrosyn) | Material |
| LA.PHAR.204 | Trabectedin (Yondelis) | Material |
| LA.PHAR.260 | Rituximab (Rituxan), Rituximab-arrx (Riabni), Rituximab-pvvr (Ruxience), Rituximab-abbs (Truxima), Rituximab-Hyaluronidase (Rituxan Hycela) | Material |
| LA.PHAR.28 | Immunization Coverage | Material |
| LA.PHAR.308 | Elotuzumab (Empliciti) | Material |
| LA.PHAR.312 | Blinatumomab (Blincyto) | Material |
| LA.PHAR.323 | Plerixafor (Mozobil) | Material |
| LA.PHAR.333 | Avelumab (Bavencio) | Material |
| LA.PHAR.361 | Tisagenlecleucel (Kymriah) | Material |
| LA.PHAR.362 | Axicabtagene ciloleucel (Yescarta) | Material |
| LA.PHAR.367 | Letermovir (Prevymis) | Material |
| LA.PHAR.371 | Triamcinolone ER Injection (Zilretta) | Material |
| LA.PHAR.40 | Octreotide Acetate (Sandostatin, Sandostatin LAR Depot, Bynfezia, Mycapssa) | Material |
| LA.PHAR.405 | Inotersen (Tegsedi) | Material |
| LA.PHAR.410 | Bortezomib (Velcade) | Material |
| LA.PHAR.415 | Ravulizumab-cwvz (Ultomiris) | Material |
| LA.PHAR.444 | Afamelanotide (Scenesse) | Material |
| LA.PHAR.445 | Brolucizumab-dbll (Beovu) | Material |
| LA.PHAR.475 | Sacituzumab Govitecan-hziy (Trodelvy) | Material |
| LA.PHAR.521 | Avalglucosidase Alfa-ngpt (Nexviazyme) | Material |
| LA.PHAR.522 | Margetuximab-cmkb (Margenza) | Material |
| LA.PHAR.542 | Talimogene laherepvec (Imlygic) | Material |
| LA.PHAR.567 | Cipaglucosidase alfa-atga--miglustat (Pombiliti- Opfolda) | Material |
| LA.PHAR.570 | Ropeginterferon Alfa-2b-njft (BESREMi) | Material |
| LA.PHAR.581 | Faricimab-svoa (Vabysmo) | Material |
| LA.PHAR.685 | Tarlatamab-dlle (Imdelltra) | Material |
| LA.PHAR.687 | Tislelizumab-jsgr (Tevimbra) | Material |
| LA.PHAR.690 | Imetelstat (Rytelo) | Material |
| LA.PHAR.595 | Eladocagene Exuparvovec-tneq (Kebilidi) | New |
| LA.PHAR.675 | Obecabtagene autoleucel (Aucatzyl) | New |
| LA.PHAR.678 | Afamitresgene autoleucel (Tecelra) | New |
| LA.PHAR.711 | Cosibelimab-Ipdl (Unloxcyt) | New |
| LA.PHAR.713 | Zenocutuzumab-zbco (Bizengri) | New |
| LA.PHAR.158 | Agalsidase Beta (Fabrazyme) | Non-Material |
| LA.PHAR.181 | Hemin (Panhematin) | Non-Material |
| LA.PHAR.189 | Ibandronate Injection (Boniva) | Non-Material |
| LA.PHAR.199 | Treprostinil (Remodulin) | Non-Material |
| LA.PHAR.282 | Parathyroid Hormone (Natpara) | Non-Material |
| LA.PHAR.300 | Bezlotoxumab (Zinplava) | Non-Material |
| LA.PHAR.301 | Erwinia Asparaginase (Erwinaze, Rylaze) | Non-Material |
| LA.PHAR.330 | Protein C Concentrate, Human (Ceprotin) | Non-Material |
| LA.PHAR.372 | Voretigene Neparvovec-rzyl (Luxturna) | Non-Material |
| LA.PHAR.402 | Emapalumab-lzsg (Gamifant) | Non-Material |
| LA.PHAR.455 | Enfortumab Vedotin-ejfv (Padcev) | Non-Material |
| LA.PHAR.459 | Iobenguane I-131 (Azedra) | Non-Material |
| LA.PHAR.465 | Teprotumumab (Tepezza) | Non-Material |
| LA.PHAR.501 | Pertuzumab/Trastuzumab/Hyaluronidase-zzxf (Phesgo) | Non-Material |
| LA.PHAR.52 | Interferon Gamma-1b (Actimmune) | Non-Material |
| LA.PHAR.523 | Naxitamab-gqgk (Danyelza) | Non-Material |
| LA.PHAR.563 | Allogenic Processed Thymus Tissue-agdc (Rethymic) | Non-Material |
| LA.PHAR.574 | Sirolimus Protein-Bound Particles (Fyarro) | Non-Material |
| LA.PHAR.610 | Sodium thiosulfate (Pedmark) | Non-Material |
| LA.PHAR.616 | Zilucoplan (Zilbrysq) | Non-Material |
| LA.PHAR.618 | Mosunetuzumab-axgb (Lunsumio) | Non-Material |
| LA.PHAR.94 | Alpha1-Proteinase Inhibitors (Aralast NP, Glassia, Prolastin-C, Zemaira) | Non-Material |
| LA.PHAR.95 | Thyrotropin Alfa (Thyrogen) | Non-Material |
| LA.CP.MP.101 | Donor Lymphocyte Infusion | Non-Material |
| LA.CP.MP.102 | Pancreas Transplantation | Material |
| LA.CP.MP.132 | Heart-Lung Transplant | Material |
| LA.CP.MP.141 | Nonmyeloablative Allogeneic Stem Cell Transplants | Material |
| LA.CP.MP.150 | Phototherapy for Neonatal Hyperbilirubinemia | Non-Material |
| LA.CP.MP.160 | Implantable Wireless Pulmonary Artery Pressure Monitoring | Non-Material |
| LA.CP.MP.162 | Tandem Transplant | Material |
| LA.CP.MP.163 | Total Parenteral Nutrition and Intradialytic Parenteral Nutrition | Material |
| LA.CP.MP.170 | Nerve Blocks and Neurolysis for Pain Management | Non-Material |
| LA.CP.MP.246 | Pediatric Kidney Transplant | Non-Material |
| LA.CP.MP.36 | Experimental Technologies | Non-Material |
| LA.CP.MP.37c | Bariatric Surgery | Non-Material |
| LA.CP.MP.40 | Gastric Electical Stimulation | Material |
| LA.CP.MP.57 | Lung Transplantation | Material |
| LA.CP.MP.69 | Intensity-Modulated Radiotherapy | Material |